Recursion Pharmaceuticals Inc (RXRX) showcases strong financial management and strategic partnerships while navigating challenges in drug discovery.

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most promising penny stocks under $5 to buy. On February 25, ...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological ...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinica ...

Guidance extended from year-end 2027 to early 2028, with operating expense reduction targets reiterated and achieved at a greater scale (now 35% year-over-year, 10% below guidance). Strategic focus ...

Recent share performance and business context Recursion Pharmaceuticals (RXRX) has drawn attention after recent trading, with the share price closing at US$3.42 and short term returns showing pressure ...

Overview Artificial intelligence seems to be transforming drug discovery in 2026, enabling faster molecule design, smarter clinical trials, and reduced R&D ...

Totaligent (OTCID: TGNT) announced the execution of a binding Letter of Intent (LOI) with GloMed Solutions Limited Liability Company, a Japanese medical aesthetics and biologics distributor, to form a ...

Supercale launches automated advert creation with Shopify and Meta Ads connections, plus a confidence score for campaign iterations.

The resulting outcome is that you have A.I. systems that have learned what it means to solve a problem that takes quite a ...

A new study warns that the greatest danger posed by artificial intelligence (AI) may not lie in faulty code but in the ...